Skip to main content
SpringerLink
Log in

Maligne Lymphome der Haut

Primär kutane T-Zell-Lymphome in der Praxis

  • Zertifizierte Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

Zusammenfassung

Kutane Lymphome unterscheiden sich in vielerlei Hinsicht von systemischen Lymphomerkrankungen. Sie haben ein eigenständiges klinisches Bild, einen völlig anderen Verlauf als ihre systemischen Verwandten und ihre Behandlung erfordert entsprechend eine abweichende Versorgung. Ihre Therapie erfolgt abhängig von der jeweiligen Krankheitsausprägung und dem Stadium.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7

Literatur

  1. Willemze R et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85.

    Article  CAS  PubMed  Google Scholar 

  2. Groves FD et al. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92(15):1240–51.

    Article  CAS  PubMed  Google Scholar 

  3. Assaf C et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges. 2007;5(8):662–8.

    Article  PubMed  Google Scholar 

  4. Marmelzat WL. Baron Jean Louis Alibert (1768-1837): his life, his times, his legacy. Cutis. 1977;19(3):355–8.

    CAS  PubMed  Google Scholar 

  5. Kazakov DV et al. Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol. 2004;18(4):397–415.

    Article  CAS  PubMed  Google Scholar 

  6. Vonderheid EC et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002;46(1):95–106.

    Article  PubMed  Google Scholar 

  7. el-Azhary RA et al. Lymphomatoid papulosis: a clinical and histopathologic review of 53 cases with leukocyte immunophenotyping, DNA flow cytometry, and T-cell receptor gene rearrangement studies. J Am Acad Dermatol. 1994;30(2 Pt 1):210–8.

    Article  CAS  PubMed  Google Scholar 

  8. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol. 1993;28(6):973–80.

    Article  CAS  PubMed  Google Scholar 

  9. Stein H et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681–95.

    CAS  PubMed  Google Scholar 

  10. Dummer R et al. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer. 2007;43(16):2321–9.

    Article  CAS  PubMed  Google Scholar 

  11. Smith BD, Wilson LD. Cutaneous lymphomas. Semin Radiat Oncol. 2007;17(3):158–68.

    Article  PubMed  Google Scholar 

  12. Kamstrup MR et al. Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. Br J Dermatol. 2012;166(2):399–404.

    Article  CAS  PubMed  Google Scholar 

  13. Stadler R. Optimal combination with PUVA: rationale and clinical trial update. Oncology (Williston Park). 2007;21(2 Suppl 1):29–32.

    Google Scholar 

  14. Stadler R et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood. 1998;92(10):3578–81.

    CAS  PubMed  Google Scholar 

  15. Duvic M et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581–93.

    CAS  PubMed  Google Scholar 

  16. Duvic M et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456–71.

    CAS  PubMed  Google Scholar 

  17. Gniadecki R et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol. 2007;157(3):433–40.

    Article  CAS  PubMed  Google Scholar 

  18. Assaf C et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol. 2006;155(2):261–6.

    Article  CAS  PubMed  Google Scholar 

  19. Booken N et al. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome. J Dtsch Dermatol Ges. 2010;8(6):428–38.

    PubMed  Google Scholar 

  20. Wollina U et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003;98(5):993–1001.

    Article  CAS  PubMed  Google Scholar 

  21. Marchi E et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer. 2005;104(11):2437–41.

    Article  CAS  PubMed  Google Scholar 

  22. Duvic M et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006;7(1):51–8.

    Article  CAS  PubMed  Google Scholar 

  23. Kaye FJ et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321(26):1784–90.

    Article  CAS  PubMed  Google Scholar 

  24. Prince HM et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(11):1870–7.

    Article  CAS  PubMed  Google Scholar 

  25. Assaf C. Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides. Dermatol Clin. 2008;26(Suppl 1):21–2.

    PubMed  Google Scholar 

  26. Kempf W et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Yu JB et al. Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;70(5):1542–5.

    Article  PubMed  Google Scholar 

  28. Terhorst D et al. Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas. Br J Dermatol. 2012;166(6):1295–300.

    Article  CAS  PubMed  Google Scholar 

  29. Stadler R et al. Short German guidelines: cutaneous lymphomas. J Dtsch Dermatol Ges. 2008;6(Suppl 1):25–31.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Dominik Förster

  2. Klinik für Dermatologie und Venerologie, Helios-Kliniken Krefeld, Lutherplatz 40, 47805, Krefeld, Deutschland

    Chalid Assaf

Authors
  1. Dominik Förster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chalid Assaf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chalid Assaf.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen leiten ließen und dass keine potenziellen Interessenkonflikte vorliegen.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Förster, D., Assaf, C. Primär kutane T-Zell-Lymphome in der Praxis. Im Focus Onkologie 18, 47–53 (2015). https://doi.org/10.1007/s15015-015-1826-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-015-1826-x

Search

Navigation